Document:

Exhibit 10.12

 

TECHNOLOGY ASSIGNMENT AGREEMENT

 

THIS TECHNOLOGY ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into this 20th day of March, 2014 by and between Catalyst Research, LLC, Bruce Bean, Donald MacKinnon and Roderick MacKinnon (each, an assignor, and collectively, the “Assignors”) and FLEX PHARMA, INC., a Delaware corporation (the “Company”).  The parties hereto agree as follows:

 

AGREEMENT

 

1.                              Assignors hereby irrevocably assign, sell, transfer and convey to the Company all right, title and interest, on a worldwide basis, in and to the technology, and intellectual property rights related to the technology, described in the patent applications set forth in Exhibit A, including any know-how and trade secrets related thereto, as well as any related work papers, data and trial results (the “Property”).  Assignors hereby acknowledge that Assignors retain no right to use the Property and agree not to challenge the validity of the Company’s ownership of the Property. This agreement is being entered into in partial consideration for the parties entering into that certain Royalty Agreement by and among the Company and the Scientific Founders (as defined therein), dated as of March 20, 2014.

 

2.                              Upon each request by the Company, without additional consideration, Assignors agree to promptly execute documents, testify and take other acts at the Company’s expense as the Company may deem necessary or desirable to procure, maintain, perfect, and enforce the full benefits, enjoyment, rights, title and interest, on a worldwide basis of the Property assigned hereunder, and render all necessary assistance in making application for and obtaining original, divisional, renewal, or reissued utility and design patents, copyrights, mask works, trademarks, trade secrets, and all other technology and intellectual property rights throughout the world related to any of the Property, in the Company’s name and for its benefit.  In the event the Company is unable for any reason, after reasonable effort, to secure each Assignor’s signature on any document needed in connection with the actions specified herein, Assignors hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest, to act for and in its behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this paragraph with the same legal force and effect as if executed by Assignors.  Assignors hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which Assignors now or may hereafter have for infringement of any Property assigned hereunder.

 

3.                              Assignors further agree to deliver to the Company upon execution of this Agreement any and all tangible manifestations of the Property, including, without limitation, all notes, records, files and tangible items of any sort in its possession or under its control relating to the Property.  Such delivery shall include all present and predecessor versions.  In addition, Assignors agree to provide to the Company from and after the execution of this Agreement and at the expense of the Company competent and knowledgeable assistance to facilitate the transfer of all information, know-how, techniques, processes and the like related to such tangible manifestation and otherwise comprising the intangible aspects of the Property.

 

1

 

4.                               Each Assignor represents and warrants to the Company that (a) Assignors, as a group, are the sole owners of the Property and have full and exclusive right to assign the rights assigned herein, (b) such Assignor has full right and power to enter into and perform this Agreement without the consent of any third party, (c) all of the Property is free and clear of all claims, liens, encumbrances and the like of any nature whatsoever, (d) the Property is an original work of Assignors, (e) such Assignor was not acting within the scope of employment or other service arrangements with any third party when conceiving, creating or otherwise performing any activity with respect to the Property, (f) the execution, delivery and performance of this Agreement does not conflict with, constitute a breach of, or in any way violate any arrangement, understanding or agreement to which such Assignor is a party or by which Assignor is bound, and (g) Assignors have maintained the Property in confidence and has not granted, directly or indirectly, any rights or interest whatsoever in the Property to any third party.

 

5.                               Each Assignor further represents and warrants to the Company that no claim, whether or not embodied in an action past or present, of any infringement, of any conflict with, or of any violation of any patent, trade secret or other intellectual property right or similar right, has been made or is pending or threatened against such Assignor relative to the Property. Assignors agree to promptly inform the Company of any such claim arising or threatened in the future with respect to the Property or any part thereof.

 

6.                               No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the parties hereto.

 

7.                               This Agreement will be governed and construed in accordance with the laws of the State of Massachusetts as applied to transactions taking place wholly within Massachusetts between Massachusetts residents. Assignors hereby expressly consent to the personal jurisdiction of the state and federal courts located in Suffolk County, Massachusetts for any lawsuit filed there against Assignors by the Company arising from or related to this Agreement.

 

8.                               If any provision of this Agreement is found invalid or unenforceable, in whole or in part, the remaining provisions and partially enforceable provisions will, nevertheless, be binding and enforceable.

 

9.                               Failure by either party to exercise any of its rights hereunder shall not constitute or be deemed a waiver or forfeiture of such rights.

 

10.                        The provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

 

(signature page follows)

 

2

 

IN WITNESS WHEREOF, the undersigned have executed this TECHNOLOGY ASSIGNMENT AGREEMENT as of the date set forth above.

 

 

	
 
    	
FLEX   PHARMA, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Brian Malone
    
	
 
    	
 
    	
(signature)
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Brian   Malone
    
	
 
    	
 
    	
(please   print name)
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
President
    

 

[Signature Page to Technology Assignment Agreement]

 

 

 

	
 
    	
ASSIGNORS
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
CATALYST   RESEARCH, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Bruce P. Bean
    
	
 
    	
 
    	
(signature)
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Bruce   P. Bean
    
	
 
    	
 
    	
(please   print name)
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Partner
    
	
 
    	
 
    
	
 
    	
/s/   Bruce P. Bean
    
	
 
    	
Name:   Bruce Bean
    
	
 
    	
 
    
	
 
    	
/s/   Donald MacKinnon
    
	
 
    	
Name:   Donald MacKinnon
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:   Roderick MacKinnon
    

 

[Signature Page to Technology Assignment Agreement]

 

 

	
 
    	
ASSIGNORS
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
CATALYST   RESEARCH, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Roderick MacKinnon
    
	
 
    	
 
    	
(signature)
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Roderick   MacKinnon
    
	
 
    	
 
    	
(please   print name)
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:   Bruce Bean
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:   Donald MacKinnon
    
	
 
    	
 
    
	
 
    	
/s/   Roderick MacKinnon
    
	
 
    	
Name:   Roderick MacKinnon
    

 

[Signature Page to Technology Assignment Agreement]

 

 

EXHIBIT A

 

DESCRIPTION OF TECHNOLOGY

 

	
Type
    	
 
    	
Country
    	
 
    	
Title
    	
 
    	
Application Serial No./
   Filing Date
    
	
Provisional
    	
 
    	
US
    	
 
    	
Methods   and compositions for Relieving Muscle Cramps
    	
 
    	
61/368,059

July   27, 2010
   (expired)
    
	
PCT
    	
 
    	
WIPO
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
PCT/US2011/045480

July   27, 2011 (abandoned)
    
	
Nonprovisional
    	
 
    	
US
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
13/191,941

July   27, 2011
   (pending)
    
	
National   Stage
    	
 
    	
EP
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
11813088.9   (pending)

July 27,   2011Exhibit 10.13

 

PATENT ASSIGNMENT AGREEMENT

 

This PATENT ASSIGNMENT AGREEMENT is dated as of March 20, 2014 (this “Assignment”), by RODERICK MACKINNON, DONALD MACKINNON, and BRUCE BEAN, individuals residing at 504 East 63rd Street, Apt 33M, New York, NY 10065, 305 East 85th St. Apt 17A, New York, NY 10028, and 20 Locke Road, Waban, MA 02468 respectively (collectively “Assignors”), and FLEX PHARMA, INC., with offices at Prudential Tower, 800 Boylston Street, c/o Longwood Fund, Boston, MA 02199 (“Assignee”).

 

WHEREAS, pursuant to the Technology Assignment Agreement among the parties dated as of March 20, 2014, Assignors agree to transfer, convey, assign and deliver to the Assignee all rights, title and interests in all presently pending patent applications and issued patents in which Assignors individually or collectively are listed as an inventor, or individually or collectively have an ownership interest that are identified on Schedule A attached hereto (collectively, the “Assigned Patents”).

 

NOW, THEREFORE, in consideration of the Agreement and the mutual covenants and promises contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                              Assignors hereby irrevocably convey, transfer, assign and deliver to Assignee, its successors and assigns, Assignors’ entire right, title and interest for the United States, its territories and possession, and all foreign countries in and to the Assigned Patents and all rights, claims and privileges pertaining thereto, including without limitation, all inventions and discoveries disclosed therein, certificates of invention and applications for certificates of invention, and any substitutions, reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations, continuations-in-part, continued prosecution applications, and corresponding foreign patents and patent applications and foreign counterparts thereof, and any and all rights to sue and recover for claims and remedies against and collect damages and other recoveries for past, present and future infringements of any or all of the foregoing, and rights for priority and protection of interests therein under the laws of any jurisdiction and hereby grants to Assignee the right to apply, obtain and hold in its own name for patents or inventor’s certificates and related rights heretofore or hereafter filed in any and all countries, including, without limitation, the right to prosecute and maintain the same and all rights to claim priority based thereon, all patents granted thereon and all reissues, extensions and renewals thereof.

 

2.                              Rights and Privileges.   All rights and privileges, including the right to sue for and receive all damages from past infringements of the Assigned Patents, will be held and enjoyed by the Assignee and its successors, assigns and other legal representatives.

 

3.                              Further Assurances.       Assignors represent and warrant to Assignee, its successors and assigns that on the date hereof that they are the exclusive owners of all right, title and interest in and to the Assigned Patents and have the right to assign the Assigned Patents, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.   Assignors each agree, at the Assignee’s expense and request: (i) to

 

1

 

assign, deliver and communicate to Assignee, its representatives, agents, successors and assigns any facts and materials relating to the Assigned Patents, including evidence for interference purposes or for other legal proceedings whenever requested and all files, documents and communications pertaining to the Assigned Patents, including all communications to and from the U.S. Patent and Trademark Office and any and all legal counsel advising on or assisting with the Assigned Patents; (ii) to testify in any interference or other legal proceedings whenever requested; (iii) to execute and deliver whenever requested all lawful papers required to make any of the foregoing provisions effective; and (iv) to generally provide all further cooperation, including taking such further action and executing such additional documents, which Assignee, its successors and assigns requests to secure, obtain or enforce proper protection for the Assigned Patents and all associated rights in this or any foreign country.

 

4.                            Authorization.    Assignors authorize and request the Commissioner of Patents and Trademarks of the United States, and any other official throughout the world whose duty is to register and record ownership in patent registrations and applications for registration of patents, to record Assignee as the assignee and owner of any and all right in the Assigned Patents.

 

5.                            Covenant Not to Sue.    Assignors hereby release, discharge, and covenant not to assert against Assignee, and Assignee’s parents, subsidiaries, contractors, customers, suppliers, affiliates, agents, employees, directors, representatives, successors, assigns, licensors, licensees, partners, joint venturers, and distributors all claims, causes, obligations, rights of action, or liabilities of any kind or nature, whether now existing or hereinafter arising and whether known or unknown, arising from or relating to proprietary rights in the Assigned Patents.

 

6.                           Miscellaneous.    This Assignment will be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, each of which such successors and permitted assigns will be deemed to be a party hereto for all purposes hereof. This Assignment and any of the terms contained herein may be amended or modified by Assignors and Assignee only in writing. This Assignment is executed by, and shall be binding upon, Assignors and Assignee and their respective successors and assigns, for the uses and purposes set forth and referred to above, effective immediately upon its delivery to Assignee.  This Assignment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts other than any provision of Massachusetts law that would result in the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. This Assignment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

7.                           Assignors hereby request and authorize Cooley, LLP, 500 Boylston St, Boston, MA 02116, to insert hereon any further identification information necessary or desirable for recordation of this document, including the filing date and application number of assigned applications or issued patents, if not yet known, when known.

 

(signature page follows)

 

2

 

IN WITNESS WHEREOF,  the parties have duly executed this Assignment as of the date first written above.

 

 

	
ASSIGNEE:
    	
FLEX PHARMA, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Brian Malone
    
	
 
    	
Name:
    	
Brian Malone
    
	
 
    	
Title:
    	
President
    

 

[Signature Page to Patent Assignment Agreement]

 

 

 

 

 

 

 

 

SCHEDULE A

 

	
Type
    	
 
    	
Country
    	
 
    	
Title
    	
 
    	
Application
    Serial No./ Filing Date
    
	
Provisional
    	
 
    	
US
    	
 
    	
Methods   and compositions for Relieving Muscle Cramps
    	
 
    	
61/368,059

July 27,   2010 (expired)
    
	
PCT
    	
 
    	
WIPO
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
PCT/US2011/045480

July 27,   2011 (abandoned)
    
	
Nonprovisional
    	
 
    	
US

 
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
13/191,941

July 27,   2011 (pending)
    
	
National   Stage
    	
 
    	
EP
    	
 
    	
Methods   and Compositions for Preventing and Relieving Muscle Cramps and For Recovery   from Neuromuscular Irritability and Fatigue Following Exercise
    	
 
    	
11813088.9   (pending)

July 27,   2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]